Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 27;12(20):12823-12842.
doi: 10.1039/d2ra00936f. eCollection 2022 Apr 22.

Novel easily separable core-shell Fe3O4/PVP/ZIF-8 nanostructure adsorbent: optimization of phosphorus removal from Fosfomycin pharmaceutical wastewater

Mai O Abdelmigeed  1 , Ahmed H Sadek  2   3 , Tamer S Ahmed  1   2
Affiliations

Novel easily separable core-shell Fe3O4/PVP/ZIF-8 nanostructure adsorbent: optimization of phosphorus removal from Fosfomycin pharmaceutical wastewater

Mai O Abdelmigeed et al. RSC Adv. .

Abstract

A new easily separable core-shell Fe3O4/PVP/ZIF-8 nanostructure adsorbent was synthesized and then examined for removal of Fosfomycin antibiotic from synthetic pharmaceutical wastewater. The removal process of Fosfomycin was expressed through testing the total phosphorus (TP). A response surface model (RSM) for Fosfomycin adsorption (as mg-P L-1) was used by carrying out the experiments using a central composite design. The adsorption model showed that Fosfomycin adsorption is directly proportional to core-shell Fe3O4/PVP/ZIF-8 nanostructure adsorbent dosage and time, and indirectly to initial Fosfomycin concentration. The removal increased by decreasing the pH to 2. The Fosfomycin removal was done at room temperature under an orbital agitation speed of 250 rpm. The adsorption capacity of core-shell Fe3O4/PVP/ZIF-8 nanostructure adsorbent reached around 1200 mg-P g-1, which is significantly higher than other MOF adsorbents reported in the literature. The maximum Langmuir adsorption capacity of the adsorbent for Fosfomycin was 126.58 mg g-1 and Fosfomycin adsorption behavior followed the Freundlich isotherm (R 2 = 0.9505) in the present study. The kinetics was best fitted by the pseudo-second-order model (R 2 = 0.9764). The RSM model was used for the adsorption process in different target modes.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts to declare.

Figures

Fig. 1
Fig. 1. Schematic diagram for the synthesis of core–shell Fe3O4/PVP/ZIF-8 nanostructure adsorbent and adsorption of Fosfomycin on its surface.
Fig. 2
Fig. 2. FTIR spectra of: (a) ZIF-8; (b) Fe3O4 nanoparticles; (c) core–shell Fe3O4/PVP/ZIF-8 nanostructure; (d) spent core–shell Fe3O4/PVP/ZIF-8 nanostructure; (e) core–shell Fe3O4/PVP/ZIF-8 nanostructure at pH = 2 for 3 h; (f) core–shell Fe3O4/PVP/ZIF-8 nanostructure at pH = 2 for 6 h.
Fig. 3
Fig. 3. (a–c) TEM images of core–shell Fe3O4/PVP/ZIF-8 nanostructure adsorbent at different magnifications demonstrating the successful formation of core–shell structures; (d–f) SEM images of core–shell Fe3O4/PVP/ZIF-8 nanostructure adsorbent at different magnifications.
Fig. 4
Fig. 4. (a) Energy-dispersive X-ray (EDX) elemental mapping of (C), (Fe), (N), (O), and (Zn); (b) EDX spectrum of core–shell Fe3O4/PVP/ZIF-8 nanostructure.
Fig. 5
Fig. 5. XRD patterns of core–shell Fe3O4/PVP/ZIF-8 nanostructure adsorbent; before Fosfomycin adsorption (lower gray line), after Fosfomycin adsorption at pH 2 for 6 h (upper red line).
Fig. 6
Fig. 6. (a) The N2 gas adsorption–desorption measurements of core–shell Fe3O4/PVP/ZIF-8 nanostructure adsorbent; (b) pore size distribution adsorption as estimated by BJH theory.
Fig. 7
Fig. 7. pH vs. % TP removal. Conditions: 0.3 g/100 mL, 30 mg-P L−1 initial concentration of TP, 200 rpm, 75 min, and 25 °C.
Fig. 8
Fig. 8. The Fosfomycin behavior in (a) acidic medium, and (b) alkaline medium.
Fig. 9
Fig. 9. Graphical representation of the 18 experiments represents the RSM model.
Fig. 10
Fig. 10. First model 3D surface response of (a) % phosphorus removal; (b) phosphorus final conc.; (c) desirability.
Fig. 11
Fig. 11. Second model 3D surface response of (a) phosphorus final conc.; (b) % phosphorus removal; (c) and (d) desirability.
Fig. 12
Fig. 12. Predicted vs. actual.
Fig. 13
Fig. 13. Kinetics models: (a) pseudo 1st order model; (b) pseudo 2nd order model; (c) intra-particle diffusion kinetic model.
Fig. 14
Fig. 14. Adsorption isotherms: (a) Langmuir isotherm; (b) Freundlich isotherm; (c) Temkin isotherm; (d) Dubinin–Radushkevich isotherm.
Fig. 15
Fig. 15. % (TP) removal for 0.3 g dosage, 30 mg-P L−1 initial concentration, pH = 2, and time of 105 minutes for each cycle.
See this image and copyright information in PMC

References

    1. Alazaiza M. Y. D. Albahnasawi A. Ali G. A. M. Bashir M. J. K. Nassani D. E. Al Maskari T. Abu Amr S. S. Abujazar M. S. S. Application of Natural Coagulants for Pharmaceutical Removal from Water and Wastewater: A Review. Water. 2022;14:1–16. doi: 10.3390/w14020140. doi: 10.3390/w14020140. - DOI - DOI
    1. Doll T. E. Frimmel F. H. Fate of pharmaceuticals - Photodegradation by simulated solar UV-light. Chemosphere. 2003;52:1757–1769. doi: 10.1016/S0045-6535(03)00446-6. doi: 10.1016/S0045-6535(03)00446-6. - DOI - DOI - PubMed
    1. Buffle M. O. Schumacher J. Salhi E. Jekel M. von Gunten U. Measurement of the initial phase of ozone decomposition in water and wastewater by means of a continuous quench-flow system: Application to disinfection and pharmaceutical oxidation. Water Res. 2006;40:1884–1894. doi: 10.1016/j.watres.2006.02.026. doi: 10.1016/j.watres.2006.02.026. - DOI - DOI - PubMed
    1. Pérez-Estrada L. A. Malato S. Gernjak W. Agüera A. Thurman E. M. Ferrer I. Fernández-Alba A. R. Photo-fenton degradation of diclofenac: Identification of main intermediates and degradation pathway. Environ. Sci. Technol. 2005;39:8300–8306. doi: 10.1021/es050794n. doi: 10.1021/es050794n. - DOI - DOI - PubMed
    1. Lee J. Farha O. K. Roberts J. Scheidt K. A. Nguyen S. T. Hupp J. T. Metal-organic framework materials as catalysts. Chem. Soc. Rev. 2009;38:1450–1459. doi: 10.1039/b807080f. doi: 10.1039/B807080F. - DOI - DOI - PubMed